SG11201506987VA - Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer - Google Patents
Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancerInfo
- Publication number
- SG11201506987VA SG11201506987VA SG11201506987VA SG11201506987VA SG11201506987VA SG 11201506987V A SG11201506987V A SG 11201506987VA SG 11201506987V A SG11201506987V A SG 11201506987VA SG 11201506987V A SG11201506987V A SG 11201506987VA SG 11201506987V A SG11201506987V A SG 11201506987VA
- Authority
- SG
- Singapore
- Prior art keywords
- patient
- calculating
- gene expression
- expression profile
- kidney cancer
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C99/00—Subject matter not provided for in other groups of this subclass
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16Z99/00—Subject matter not provided for in other main groups of this subclass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Medical Informatics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Hospice & Palliative Care (AREA)
- Computing Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361829100P | 2013-05-30 | 2013-05-30 | |
PCT/US2014/040003 WO2014194078A1 (en) | 2013-05-30 | 2014-05-29 | Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201506987VA true SG11201506987VA (en) | 2015-10-29 |
Family
ID=51989393
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201506987VA SG11201506987VA (en) | 2013-05-30 | 2014-05-29 | Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer |
SG10201709537PA SG10201709537PA (en) | 2013-05-30 | 2014-05-29 | Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201709537PA SG10201709537PA (en) | 2013-05-30 | 2014-05-29 | Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer |
Country Status (12)
Country | Link |
---|---|
US (3) | US10181008B2 (es) |
EP (2) | EP3004392B1 (es) |
JP (3) | JP2016521979A (es) |
AU (2) | AU2014274135B2 (es) |
CA (2) | CA3093128C (es) |
DK (1) | DK3004392T3 (es) |
ES (1) | ES2829415T3 (es) |
HK (1) | HK1223132A1 (es) |
IL (2) | IL240919B (es) |
MX (2) | MX369911B (es) |
SG (2) | SG11201506987VA (es) |
WO (1) | WO2014194078A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018187767A1 (en) * | 2017-04-06 | 2018-10-11 | The Regents Of The University Of California | Predicting, diagnosing, and treating nausea and vomiting of pregnancy |
SG11202002711WA (en) | 2017-10-12 | 2020-04-29 | Nantomics Llc | Cancer score for assessment and response prediction from biological fluids |
KR102280204B1 (ko) * | 2018-12-13 | 2021-07-21 | 연세대학교 산학협력단 | 신장 세포 암의 종양의 병리학적 등급에 대한 정보를 제공하기 위한 방법 및 장치 |
WO2020146745A1 (en) * | 2019-01-11 | 2020-07-16 | Quadrus Medical Technologies, Inc. | Systems and methods for assessing and evaluating renal health diagnosis, staging, and therapy recommendation |
EP3978629A1 (en) | 2020-10-01 | 2022-04-06 | Koninklijke Philips N.V. | Prediction of an outcome of a bladder or kidney cancer subject |
CN113593640B (zh) * | 2021-08-03 | 2023-07-28 | 哈尔滨市米杰生物科技有限公司 | 一种鳞癌组织功能状态与细胞组分评估方法及系统 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7135314B1 (en) | 1997-04-17 | 2006-11-14 | Cell Therapeutics, Inc. | Human phosphatidic acid phosphatase |
EP1246917B1 (en) | 2000-01-13 | 2009-03-04 | Genentech, Inc. | Human stra6 polypeptides |
US6475855B1 (en) | 2000-03-01 | 2002-11-05 | Micron Technology, Inc. | Method of forming integrated circuitry, method of forming a capacitor and method of forming DRAM integrated circuitry |
DE10126344A1 (de) | 2000-07-14 | 2002-01-24 | Max Planck Gesellschaft | Apoptose-induzierende DNA-Sequenzen |
AU2001294842A1 (en) | 2000-09-28 | 2002-04-08 | Atairgin Technologies, Inc. | A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes |
US20030109434A1 (en) | 2001-03-19 | 2003-06-12 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of kidney cancer |
CA2442820A1 (en) * | 2001-03-29 | 2002-10-10 | Van Andel Institute | Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification |
CA2451074C (en) | 2001-06-18 | 2014-02-11 | Rosetta Inpharmatics, Inc. | Diagnosis and prognosis of breast cancer patients |
US7470509B2 (en) | 2002-02-08 | 2008-12-30 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer |
ES2616800T3 (es) | 2002-03-13 | 2017-06-14 | Genomic Health, Inc. | Obtención de perfil de expresión génica en tejidos tumorales biopsiados |
WO2004032842A2 (en) | 2002-10-04 | 2004-04-22 | Van Andel Research Institute | Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers |
US7611839B2 (en) | 2002-11-21 | 2009-11-03 | Wyeth | Methods for diagnosing RCC and other solid tumors |
AU2004235395A1 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for prognosis and treatment of solid tumors |
JP4680898B2 (ja) | 2003-06-24 | 2011-05-11 | ジェノミック ヘルス, インコーポレイテッド | 癌再発の可能性の予測 |
WO2005005661A2 (en) | 2003-07-02 | 2005-01-20 | Novartis Ag | Genes regulated in ovarian cancer as prognostic and therapeutic targets |
US20050002904A1 (en) | 2003-07-03 | 2005-01-06 | Wary Kishore K. | Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP) |
CA2531967C (en) | 2003-07-10 | 2013-07-16 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
JP2005211023A (ja) | 2004-01-30 | 2005-08-11 | Hayashibara Biochem Lab Inc | 腎細胞癌の転移若しくは再発の可能性を予測する方法 |
US20070224596A1 (en) | 2004-04-09 | 2007-09-27 | Mariana Nacht | Compositions and methods for the modifying hypoxia induced gene regulation |
JP5813908B2 (ja) * | 2004-04-09 | 2015-11-17 | ジェノミック ヘルス, インコーポレイテッド | 化学療法剤に対する応答を予測するための遺伝子発現マーカー |
US7482129B2 (en) * | 2004-05-04 | 2009-01-27 | Institute Of Virology, Slovak Academy Of Sciences | MN/CA IX/CA9 and Renal Cancer Prognosis |
JP2008500057A (ja) | 2004-05-27 | 2008-01-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | Impdh経路の阻害をモニタリングするためのバイオマーカー |
US7587279B2 (en) | 2004-07-06 | 2009-09-08 | Genomic Health | Method for quantitative PCR data analysis system (QDAS) |
US20080119367A1 (en) | 2004-12-17 | 2008-05-22 | Mayo Foundation For Medical Education And Research | Prognosis of Renal Cell Carcinoma |
WO2006083986A2 (en) | 2005-02-01 | 2006-08-10 | Government Of The U.S.A, As Represented By The Secretary Department Of Health & Human Services | Biomarkers for tissue status |
RU2007129864A (ru) | 2005-02-18 | 2009-03-27 | Вайет (Us) | Фармакогеномные маркеры для прогнозирования солидных опухолей |
WO2006124022A1 (en) | 2005-05-13 | 2006-11-23 | Vanandel Research Institute | Microarray gene expression profiling in subtypes of clear cell renal cell carcinoma |
EP1910564A1 (en) | 2005-05-13 | 2008-04-16 | Duke University | Gene expression signatures for oncogenic pathway deregulation |
US20070037186A1 (en) | 2005-05-20 | 2007-02-15 | Yuqiu Jiang | Thyroid fine needle aspiration molecular assay |
MX2007015416A (es) | 2005-06-08 | 2008-02-19 | Millennium Pharm Inc | Metodos para la identificacion, evaluacion y tratamiento de pacientes con terapia contra cancer. |
WO2006135886A2 (en) | 2005-06-13 | 2006-12-21 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
CA2612021A1 (en) | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
ATE456557T1 (de) | 2005-06-15 | 2010-02-15 | Pfizer Ltd | Substituierte arylpyrazole zur verwendung gegen parasiten |
EP2154245B1 (en) | 2005-09-02 | 2015-11-11 | Toray Industries, Inc. | Composition and method for diagnosing kidney cancer and for predicting prognosis for kidney cancer patient |
ATE531820T1 (de) | 2005-09-14 | 2011-11-15 | Human Genetic Signatures Pty | Gesundheitszustandstest |
EP2332984A3 (en) | 2005-09-30 | 2011-10-12 | Universiteit Maastricht | Tumor angiogenesis associated genes and a method for their identification |
EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
EP1960551A2 (en) | 2005-12-01 | 2008-08-27 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
MX2008007650A (es) | 2005-12-16 | 2008-10-20 | Genentech Inc | Metodo para diagnostico, pronostico y tratamiento de glioma. |
US20080242606A1 (en) | 2006-06-06 | 2008-10-02 | Zhong Jiang | Use of IMP3 as a Prognostic Marker for Cancer |
EP2046973A4 (en) | 2006-08-10 | 2010-04-07 | Millennium Pharm Inc | METHODS OF IDENTIFYING, EVALUATING, AND TREATING PATIENTS SUBJECTED TO ANTICANCER THERAPY |
WO2008021115A2 (en) | 2006-08-14 | 2008-02-21 | The Brigham And Women's Hospital, Inc. | Diagnostic tests using gene expression ratios |
US9034574B2 (en) * | 2006-12-27 | 2015-05-19 | The Johns Hopkins University | Agents for reversing epigenetic silencing of genes |
US20080286273A1 (en) | 2007-05-02 | 2008-11-20 | Siemens Medical Solutions Usa, Inc. | Knowledge-Based Proliferation Signatures and Methods of Use |
EP1990417A1 (en) | 2007-05-11 | 2008-11-12 | Universität Bayreuth | Archaeal plasmid vector system |
WO2009105640A1 (en) | 2008-02-22 | 2009-08-27 | Virginia Commonwealth University | Signatures associated with rejection or recurrence of cancer |
CN105039523A (zh) | 2008-11-17 | 2015-11-11 | 威拉赛特公司 | 用于疾病诊断的分子表达谱的方法和组合物 |
CA2766703A1 (en) | 2009-06-26 | 2010-12-29 | Noviogendix Research B.V. | Molecular markers in kidney cancer |
US9005891B2 (en) | 2009-11-10 | 2015-04-14 | Genomic Health, Inc. | Methods for depleting RNA from nucleic acid samples |
CA2776751C (en) * | 2009-11-23 | 2019-07-02 | Genomic Health, Inc. | Methods to predict clinical outcome of cancer |
NZ600268A (en) * | 2010-01-11 | 2014-08-29 | Genomic Health Inc | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
JP2014519340A (ja) * | 2011-06-16 | 2014-08-14 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス.アー.エール.エル. | バイオマーカー組成物および方法 |
WO2013028807A2 (en) * | 2011-08-22 | 2013-02-28 | Somalogic, Inc. | Renal cell carcinoma biomarkers and uses thereof |
-
2014
- 2014-05-29 JP JP2016516815A patent/JP2016521979A/ja active Pending
- 2014-05-29 EP EP14804772.3A patent/EP3004392B1/en active Active
- 2014-05-29 DK DK14804772.3T patent/DK3004392T3/da active
- 2014-05-29 AU AU2014274135A patent/AU2014274135B2/en active Active
- 2014-05-29 EP EP20198766.6A patent/EP3825420A1/en not_active Withdrawn
- 2014-05-29 US US14/779,428 patent/US10181008B2/en active Active
- 2014-05-29 MX MX2015012782A patent/MX369911B/es active IP Right Grant
- 2014-05-29 CA CA3093128A patent/CA3093128C/en active Active
- 2014-05-29 SG SG11201506987VA patent/SG11201506987VA/en unknown
- 2014-05-29 SG SG10201709537PA patent/SG10201709537PA/en unknown
- 2014-05-29 CA CA2903878A patent/CA2903878C/en active Active
- 2014-05-29 ES ES14804772T patent/ES2829415T3/es active Active
- 2014-05-29 WO PCT/US2014/040003 patent/WO2014194078A1/en active Application Filing
-
2015
- 2015-08-30 IL IL240919A patent/IL240919B/en active IP Right Grant
- 2015-09-14 MX MX2019013953A patent/MX2019013953A/es unknown
-
2016
- 2016-09-30 HK HK16111438.9A patent/HK1223132A1/zh unknown
-
2018
- 2018-07-17 JP JP2018134242A patent/JP2018161151A/ja active Pending
- 2018-11-26 US US16/199,707 patent/US20190095575A1/en not_active Abandoned
-
2020
- 2020-07-06 AU AU2020204502A patent/AU2020204502B2/en active Active
- 2020-08-18 JP JP2020138078A patent/JP7301798B2/ja active Active
- 2020-11-02 US US17/086,850 patent/US11551782B2/en active Active
-
2021
- 2021-05-30 IL IL283548A patent/IL283548A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283548A (en) | Gene expression profile algorithm to calculate recurrence score for prostate cancer patients | |
HK1213444A1 (zh) | 癌症的治療 | |
SG11201605585SA (en) | Targeted therapy for small cell lung cancer | |
EP3023101A4 (en) | Therapeutic agent for fgfr inhibitor-resistant cancer | |
GB201322725D0 (en) | Cancer therapy | |
EP2958571C0 (en) | DNA HYPOMETHYLING AGENTS FOR CANCER THERAPY | |
HK1220900A1 (zh) | 癌症的治療 | |
EP2994148B8 (en) | Cancer therapy | |
EP3077544A4 (en) | Rationale-based design of a targeted therapy for cancer | |
GB201312184D0 (en) | Touchscreen keyboard | |
PL2831110T3 (pl) | Terapia anty-EMP2 zmniejsza ilość rakowych komórek macierzystych | |
EP3044593A4 (en) | Cancer therapy | |
EP3069284A4 (en) | Computer-assisted modeling for treatment design | |
IL240218A0 (en) | Catheter for blockage between a nerve and an organ | |
EP2961412A4 (en) | CANCER THERAPY | |
EP2885428A4 (en) | GENE EXPRESSION PROFILE ASSOCIATED WITH PROSTATE CANCER | |
PL2950869T3 (pl) | Cewnik o zmiennej krzywiźnie | |
EP2882869A4 (en) | PROSTATE CANCER GENE EXPRESSION PROFILES | |
HK1218939A1 (zh) | 用於非小細胞肺癌療法的藥物選擇 | |
EP2839034A4 (en) | GENE EXPRESSION PROFILES ASSOCIATED WITH METASTASIC BREAST CANCER | |
GB201518731D0 (en) | Tumour Therapy | |
EP3013332A4 (en) | Cancer treatment | |
GB201317213D0 (en) | Cancer Therapy | |
IL239231A0 (en) | Combined cancer treatment | |
GB201308365D0 (en) | Tumour therapy |